Multicenter real-world retrospective study demonstrates rapid efficacy of efgartigimod in generalized myasthenia gravis, suggesting a valuable treatment option for acute exacerbations.
Efgartigimod demonstrates rapid, significant efficacy in gMG acute exacerbations/worsening, supporting its role as a valuable therapeutic option for this high-risk population.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: